Omadacycline - Associated Anticardiolipin Antibody Positivity and Hypercoagulable State: A Case Report and Review of Tetracycline - Induced Immune Dysregulation
Abstract
We present the case of an 18-year-old previously healthy female diagnosed with Mycoplasma pneumoniae pneumonia who developed marked elevation in D-dimer and fibrinogen degradation products, along with de novo positivity for both IgG and IgM anticardiolipin antibodies, shortly after initiating intravenous omadacycline therapy. These findings occurred in the absence of known antiphospholipid syndrome or other autoimmune conditions. The patient also experienced gastrointestinal symptoms and skin rashes. After discontinuation of omadacycline and supportive care, her condition improved. This case highlights the temporal association between omadacycline administration and the emergence of immune-coagulative dysregulation. Given that Mycoplasma pneumoniae infection itself can cause similar extrapulmonary manifestations, a definitive causal link cannot be established. This case suggests a probable, though rare, association between omadacycline and immune-coagulative dysregulation. Clinicians should be vigilant for such signals, particularly in patients developing early cutaneous or gastrointestinal symptoms during therapy.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.